Clinical & Scientific

New data reveals a novel cancer drug shrinks brain metastases in over half of small cell lung cancer patients, offering hope where options are scarce.

A new platform watches individual tumor cells to link behavior with biology, offering a powerful tool against treatment resistance in cancers like glioblastoma.

For the first time, a major regulatory body has approved a drug name created by AI, signaling a new era for the highly regulated pharmaceutical industry.

Early Phase 2 data shows invikafusp alfa plus TRODELVY® yields complete responses in heavily pretreated breast cancer, offering a potential new lifeline.

Biopharma leader Dr. Gavin Barnard joins ATUM as CSO, aiming to leverage AI and advanced tech to fast-track complex therapies from the lab to the clinic.

A new biotech player is advancing a first-in-class cancer drug that combines two payloads to fight tumors that have become resistant to current therapies.

A parent-led company gains a U.S. patent for a diazoxide formulation, offering new hope for managing behavioral symptoms in Prader-Willi syndrome.

AVITA Medical's Cohealyx shows a nearly 20-day reduction in time to skin grafting, a breakthrough that could reshape patient recovery and the market.

A Yale spinout's AI-powered EEG platform promises to prevent birth injuries and cut C-sections by monitoring the fetal brain, not just heart rate.

A jury found Abbott's Similac caused a fatal gut disease in premature infants, igniting a legal firestorm over what the formula giant knew and when.

A new partnership between a Chinese biotech and a Brazilian public institute aims to slash the $500k cost of CAR-T therapy, making it accessible to all.

Jetstream Venture Fund's deals with Surf Therapeutics and Hill Research signal a new era of accessible venture capital backing transformative technologies.

China's Gan & Lee partners with JW Pharmaceutical to launch its novel bi-weekly GLP-1 drug, Bofanglutide, into the competitive South Korean market.

Following a massive stock surge, Forte Biosciences is raising $150M. The funds are crucial for a pivotal year of clinical trials for its autoimmune drug.

Rune Labs launches StrivePD Guardian, an AI companion using Anthropic's Claude and a massive dataset to offer 24/7 personalized support for patients.

With a $137M war chest, Sidewinder Therapeutics is advancing a new class of ultra-precise cancer drugs aimed at tumors that have long evaded treatment.

Century Health and VCU are building a massive AI-driven database to decode steatotic liver disease, a silent epidemic affecting nearly 2 billion people.

With a new patent for its drug ALPHA-1062, Alpha Cognition may become a first-mover in the $14 billion traumatic brain injury market, which has no approved therapies.

In a tough biotech market, NewcelX's $1.35M financing at a 30% premium signals strong confidence in its pioneering stem cell therapy for Type 1 Diabetes.

As China surpasses the US in key research metrics, a new English platform aims to bridge the information gap for global scientists and innovators.